Does the HDRB arm also treat a larger volume of normal tissue? Does the 36 Gy in 12 fractions of the HDRB Arm treat a larger target volume? pelvic nodes?
Please clarify this line: Alternatively, the virtual HDRB approach potentials allows for some variation in fraction size sensitivity within and between tumors.
Urethral visualization via temporary catheterization or equivalent approaches will be performed. What equivalent approaches?
All patients require intra-prostatic markers with intra-fraction motion management strategies to ensure accurate treatment delivery. Are you correcting for translations and rotations or just translations? 
REVIEWER

GENERAL COMMENTS
Thank you for the submission and its a really interesting trial design. I only make these points to assist = there's nothing of real concern.
In the eligibility criteria, I wonder if you need to include MRI defined estimate prostate volume >100cc (so that you don't end up with investigators entering patients with borderline volume.
Concurrent hormonal therapy -is single agent bicalutamide 150mg od allowed?
Aim 1 -I agree with your estimation of 5yr BCC in this patient group. I do have some concerns with the 2-arm nature of the study and that both arms are to some experimental (as your standard protocol appears to 60gy/ 20Fr); comparing the SBRT and HDRB arms you actually have several variations -including overall time, total dose and dose per fraction; whether HDRB is dose escalation compared to SBRT depends on the alpha-beta ratio and whether time is important, which is currently an open debate. I do agree that the HDRB arm needs to be a lot better than the SBRT arm to make it cost effective and acceptable to patients and healthcare commissioners (in the UK anyway)! Aim 2 -I couldn't see any guidance for centres as whether to adopt the central KBP planning or to stay with their local plan. This could lead to centre-by-centre variation and introduce unintended bias.
Finally did you consider delivering a subvolume boost to MRIdefined lesions? Good luck
VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
This is a well-written manuscript describing a multi-institutional Phase III trial of SBRT plus or minus supplemental IMRT for unfavorable prostate cancer. This series is well suited for publication in BMJ Open because this study is very important. The authors are clearly experts in the field and the paper is for the most part scientifically accurate.
Thank you for this kind overall assessment.
Major Compulsory Revisions:
The primary endpoint is BDFS. If the HDRB arm has a higher BDFS but is more toxic (> 10% grade 3 toxicity) in the multi-institutional setting would you recommend HDRB as your standard treatment for all future patients? Would it make sense to have two primary endpoints BDFS and Grade 3 toxicity? QOL?
Amongst all possible endpoints, disease control is generally considered the most important, and as such we have powered the trial for biochemical-clinical control. Late toxicity in particular is also of relevance, and this is an important secondary endpoint. We have now added the reference for our phase 2 'Virtual HDRB' experience (Pryor et al 2019), which shows ~3% transient G3 toxicity, which makes this unlikely to be a common event in the current study. The vast majority of recent and current randomized trials in prostate cancer radiotherapy treatment intensification follow this similar approach. Rather than trying to add the complexity of co-primary endpoints, we aim to report efficacy as the primary endpoint with toxicity (and other factors including patient reported quality of life) in a secondary manner, and then allow clinicians to make their own conclusions regarding any trade-offs.
Please justify the usage of six months of ADT in favorable high-risk patients.
The recent TROG RADAR study showed a 3% improvement in prostate cancer specific survival for a largely very high risk population for 18 months of ADT compared with 6 months. In our more favourable high risk population where we both mandate baseline PSMA-PET staging and exclude men with risk factors suggestive of a >15% risk of metastatic failure, the absolute benefits of a longer course of ADT would be smaller. This is now referenced and expanded in the methods as follows:
All patients will receive a total of six months of Androgen Deprivation Therapy (ADT).(33, 34) The use of PSMA PET staging for high risk men, and criteria to exclude very high risk features should minimize any potential additive benefits of longer course ADT in this population.
The ASCEND trial does not show differences in arms until after 5 years. It is unlikely that there will be a large difference in BDFS at 5 years between arms in this study. Why not BDFS at 7-10 years?
Even for ASCEND, despite improved biochemical control with >10yr follow-up, the use of brachytherapy continues to fall. In the strengths and limitations section, we acknowledge that the use of a medium term surrogate endpoint of Biochemical Clinical Control at 5 years is less robust than a longer term survival endpoint.
Minor Compulsory Revisions: Please clarify this line: Alternatively, the virtual HDRB approach potentials allows for some variation in fraction size sensitivity within and between tumors.
The relevant sentence has been reworded and expanded to address this:
The virtual HDRB approach also acknowledges the possibility of heterogeneity in the alpha-beta ratio, and therefore potentially allows for some variation in fraction size sensitivity within and between tumours.
The wording of this line has been amended to improve clarity:
Urethral positional estimation via temporary catheterization or equivalent approaches such as highresolution sagittal MRI can be performed.
All patients require intra-prostatic markers with intra-fraction motion management strategies to ensure accurate treatment delivery. Are you correcting for translations and rotations or just translations?
Translations only. Our rationale for not correcting for rotational motion is expanded and referenced now:
Rotational corrections do not need to be applied due to minimal dosimetric impact from such motion. (Wolf et al, 2019) Reviewer: 2
Thank you for the submission and its a really interesting trial design.
I only make these points to assist = there's nothing of real concern.
Further eligibility criteria have been added as below:
Prostate volume <100cc, and patients can only be randomized after a plan has been generated showing that protocol compliant treatment can be performed.
Due to the vast majority of randomized date for hormonal therapy with radiotherapy using ADT or maximal androgen blockade, we have not allowed single agent antiandrogen treatment.
Aim 1 -I agree with your estimation of 5yr BCC in this patient group. I do have some concerns with the 2-arm nature of the study and that both arms are to some experimental (as your standard protocol appears to 60gy/ 20Fr); comparing the SBRT and HDRB arms you actually have several variationsincluding overall time, total dose and dose per fraction; whether HDRB is dose escalation compared to SBRT depends on the alpha-beta ratio and whether time is important, which is currently an open debate. I do agree that the HDRB arm needs to be a lot better than the SBRT arm to make it cost effective and acceptable to patients and healthcare commissioners (in the UK anyway)!
